During the last session, Oncology Institute Inc (NASDAQ:TOI)’s traded shares were 0.49 million, with the beta value of the company hitting 0.29. At the end of the trading day, the stock’s price was $1.14, reflecting an intraday gain of 2.70% or $0.03. The 52-week high for the TOI share is $1.78, that puts it down -56.14 from that peak though still a striking 88.6% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $86.36M, and the average intraday trading volume over the past 10 days was 0.73 million shares, and the average trade volume was 782.86K shares over the past three months.
Oncology Institute Inc (TOI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. TOI has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Oncology Institute Inc (NASDAQ:TOI) trade information
Oncology Institute Inc (TOI) registered a 2.70% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.70% in intraday trading to $1.14, hitting a weekly high. The stock’s 5-day price performance is 14.43%, and it has moved by 28.08% in 30 days. Based on these gigs, the overall price performance for the year is -32.54%. The short interest in Oncology Institute Inc (NASDAQ:TOI) is 1.1 million shares and it means that shorts have 2.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 85.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $10 respectively. As a result, TOI is trading at a discount of -777.19% off the target high and -426.32% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -488.57%.
TOI Dividends
Oncology Institute Inc is due to release its next quarterly earnings on 2024-Aug-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Oncology Institute Inc (NASDAQ:TOI)’s Major holders
Oncology Institute Inc insiders own 14.81% of total outstanding shares while institutional holders control 39.94%, with the float percentage being 46.88%. FMR LLC is the largest shareholder of the company, while 40.0 institutions own stock in it. As of 2024-06-30, the company held over 4.75 million shares (or 6.4005% of all shares), a total value of $2.19 million in shares.
The next largest institutional holding, with 3.36 million shares, is of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)’s that is approximately 4.5263% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.55 million.
Also, the Mutual Funds coming in first place with the largest holdings of Oncology Institute Inc (TOI) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.27 shares. This amounts to just over 1.68 percent of the company’s overall shares, with a $1.45 million market value. The same data shows that the other fund manager holds slightly less at 422.98, or about 0.56% of the stock, which is worth about $0.48 million.
